Effectiveness of Amantadine Hydrochloride in the Reduction of Chronic Traumatic Brain Injury Irritability and Aggression
Authors:
- Allison K. BickettABAllison K. Bickett
- James H. NortonJNJames H. Norton
- Rashmi PershadRPRashmi Pershad
- 1 September 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Head Trauma Rehabilitation
- Vol. 29 (5) , 391-399
Abstract
Following traumatic brain injury (TBI), individuals may experience chronic problems with irritability or aggression, which may need treatment to minimize the negative impact on their relationships, home life, social interactions, community participation, and employment : To test the a priori hypothesis that amantadine reduces irritability (primary hypothesis) and aggression (secondary hypothesis) among individuals greater than 6 months post-TBI METHODS:: A total of 76 individuals greater than 6 months post-TBI referred for irritability management were enrolled in a parallel-group, randomized, double-blind, placebo-controlled trial of amantadine (n = 38) versus placebo (n = 38). Study participants were randomly assigned to receive amantadine hydrochloride 100 mg twice daily versus equivalent placebo for 28 days. Symptoms of irritability and aggression were measured before and after treatment using the Neuropsychiatric Inventory Irritability (NPI-I) and Aggression (NPI-A) domains, as well as the NPI-Distress for these domains : In the amantadine group, 80.56% improved at least 3 points on the NPI-I, compared with 44.44% in the group that received placebo (P = .0016). Mean change in NPI-I was -4.3 in the amantadine group and -2.6 in the placebo group (P = .0085). When excluding individuals with minimal to no baseline aggression, mean change in NPI-A was -4.56 in the amantadine group and -2.46 in the placebo group (P = .046). Mean changes in NPI-I and NPI-A Distress were not statistically significant between the amantadine and placebo groups. Adverse event occurrence did not differ between the 2 groups : Amantadine 100 mg every morning and at noon appears an effective and safe means of reducing frequency and severity of irritability and aggression among individuals with TBI and sufficient creatinine clearance.Keywords
This publication has 38 references indexed in Scilit:
- Neuropsychiatric Disorders in Persons With Severe Traumatic Brain InjuryJournal of Head Trauma Rehabilitation, 2011
- Marital Adjustment and Stability Following Traumatic Brain InjuryJournal of Head Trauma Rehabilitation, 2011
- Neurobiology of Aggression and ViolenceAmerican Journal of Psychiatry, 2008
- Guidelines for the Pharmacologic Treatment of Neurobehavioral Sequelae of Traumatic Brain InjuryJournal of Neurotrauma, 2006
- Use of the Neuropsychiatric Inventory in traumatic brain injury: A pilot investigation.Rehabilitation Psychology, 2006
- Neurobehavioral Effects of Amantadine After Pediatric Traumatic Brain InjuryJournal of Head Trauma Rehabilitation, 2005
- Cognitive and behavioural efficacy of amantadine in acute traumatic brain injury: an initial double-blind placebo-controlled studyBrain Injury, 1999
- N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injuryBrain Injury, 1995
- The frontal lobes and traumatic brain injuryThe Journal of Neuropsychiatry and Clinical Neurosciences, 1994
- Amphetamine, Haloperidol, and Experience Interact to Affect Rate of Recovery After Motor Cortex InjuryScience, 1982